Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes may be less welcome. Here's what to expect.
It’s time to treat obesity as a chronic disease and have Medicare cover these life-changing AOMs. By taking action now, we ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
Opinion: It’s time we prioritize innovation and invest in solutions that truly address the root cause of this chronic and ...
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could ...
These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices ...
Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...